Caffeine preserves quiet sleep in preterm neonates.

Area of Science:

• Neonatal Medicine
• Pharmacology
• Developmental Neuroscience

Background:

• Caffeine citrate is a common treatment for apnea of prematurity (AOP) in neonatal intensive care units.
• Understanding caffeine's impact on sleep-wake cycles is crucial for optimizing care in vulnerable preterm infants.

Purpose of the Study:

• To investigate the effects of caffeine citrate on sleep-wake behavior in preterm neonates.
• To correlate caffeine concentrations with specific sleep stages and wakefulness.

Main Methods:

• Observational study of 64 preterm neonates (<32 weeks GA or <1500g birthweight).
• Sleep-wake behavior scored into active sleep, quiet sleep, and wakefulness.
• Pharmacokinetic modeling used to simulate individual neonate caffeine concentrations.

Main Results:

• In neonates with gestational age ≥28 weeks, increased caffeine levels correlated with increased wakefulness and decreased active sleep.
• Quiet sleep remained unchanged across varying caffeine concentrations in this group.
• No significant caffeine effects on sleep-wake behavior were observed in neonates with gestational age <28 weeks.

Conclusions:

• Caffeine citrate increases wakefulness and alertness in preterm neonates (GA ≥28 weeks) at the expense of active sleep.
• The drug does not appear to negatively impact quiet sleep, suggesting regeneration time may be preserved.
• Further research is needed to understand effects in extremely preterm infants (GA <28 weeks).